Cutaneous T-Cell Lymphoma

    October 2001 in “ Dermatologic Clinics ”
    Narin Apisarnthanarax, Madeleine Duvic
    Studysummary In this study, subcutaneous recombinant human IL-12 showed a 43% partial response rate in early-stage mycosis fungoides patients refractory to previous treatments, with generally mild to moderate adverse events reported.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on sciencedirect.com →
    Discuss this study in the Community →

    Research cited in this study 1

    1. Interferon Alfa-2a in the Treatment of Cutaneous T Cell Lymphoma Journal of The American Academy of Dermatology · 1989